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Abstract
Background
Epidemiological studies of neurological complications in patients with hematological malig-
nancies are scant. The objective of the study was to identify determinants of survival in
patients with hematological malignancy and neurological failure.
Methods
Post hoc analysis of a prospective study of adults with hematological malignancies admitted
for any reason to one of 17 university or university-affiliated participating ICUs in France and
Belgium (2010–2012). The primary outcome was vital status at hospital discharge.
Results
Of the 1011 patients enrolled initially, 226 (22.4%) had neurological failure. Presenting mani-
festations were dominated by drowsiness or stupor (65%), coma (32%), weakness (26%),
and seizures (19%). Neuroimaging, lumbar puncture, and electroencephalography were
performed in 113 (50%), 73 (32%), and 63 (28%) patients, respectively. A neurosurgical
biopsy was done in 1 patient. Hospital mortality was 50%. By multivariate analysis, factors
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independently associated with higher hospital mortality were poor performance status (odds
ratio [OR], 3.99; 95%CI, 1.82–9.39; P = 0.0009), non-Hodgkin’s lymphoma (OR, 2.60; 95%
CI, 1.35–5.15; P = 0.005), shock (OR, 1.95; 95%CI, 1.04–3.72; P = 0.04), and respiratory
failure (OR, 2.18; 95%CI, 1.14–4.25; P = 0.02); and factors independently associated with
lower hospital mortality were GCS score on day 1 (OR, 0.88/point; 95%CI, 0.81–0.95; P =
0.0009) and autologous stem cell transplantation (OR, 0.25; 95%CI, 0.07–0.75; P = 0.02).
Conclusions
In ICU patients with hematological malignancies, neurological failure is common and often
fatal. Independent predictors of higher hospital mortality were type of underlying hematologi-
cal malignancy, poor performance status, hemodynamic and respiratory failures, and sever-
ity of consciousness impairment. Knowledge of these risk factors might help to optimize
management strategies.
Introduction
Recent advances in the management of hematological malignancies,[1] including the intro-
duction of new drugs, have improved survival and changed the circumstances of admission to
the intensive care unit (ICU). New studies of organ support techniques[2–7] have produced
refinements in management strategies.[8, 9]
Neurological manifestations have been reported in up to 17% of patients with hematologi-
cal malignancies.[10] They cover a broad spectrum, as described in several reviews.[11–13]
Neurological involvement may be direct, i.e., due to infiltration of the central nervous system
(CNS) by the malignant cells; or indirect, i.e., caused by vascular, metabolic, toxic, infectious,
or paraneoplastic events.[11, 13]
Epidemiological studies of neurological complications in patients with hematological
malignancies are scant and generally relied on retrospective data collection. Few of them
focused on severe complications requiring admission to the ICU,[10] which were found to
carry a hospital mortality rate of 45%.[10] Further information would help clinicians to iden-
tify those patients most likely to benefit from aggressive diagnostic and therapeutic strategies.
To help fill this knowledge gap, we conducted a prospective cohort study in a large popula-
tion of patients with hematological malignancies who required ICU admission for any reason.
Here, we focus on a post hoc analysis of the incidence, causes, outcomes, and risk factors of
neurological complications.
Patients and methods
The appropriate ethics committees in France (CEERB Bichat, 0235) and Belgium (Ghent Uni-
versity Hospital Ethical committee) approved this noninterventional prospective cohort study.
In accordance with French law, the CEERB Bichat ethics committee waived the requirement
for obtaining written consent from participants or next of kin. Participants or next of kin were
given an informed consent document and all of them gave a verbal consent. This was traced
and notified in the hospital chart. In accordance with Belgium law, the Ghent University Hos-
pital Ethical committee required a written consent from all participants. Finally, in both coun-
tries, informed consent was obtained from all participants or next of kin included in the study.
[14]
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Abbreviations: ICU, intensive care unit; CNS,
central nervous system; GCS, Glasgow Coma
Scale; SAPS-II, Simplified Acute Physiology Score
II; SOFA, Sepsis-Related Organ Failure
Assessment; CT, Computed tomography; CSF,
Cerebrospinal fluid.
Patients
We included consecutive patients with hematological malignancies who were admitted for any
reason to one of 17 ICUs in university or university-affiliated hospitals in France and Belgium
between January 1, 2010, and May 1, 2011. Noninclusion criteria were age younger than 18
years, ICU admission only to maximize the safety of a procedure, and malignancy in remission
for the past 5 years or longer. ICU patients received follow-up for 1 year after ICU discharge.
Neurological failure was defined as a neurological disorder requiring ICU admission for
monitoring or organ support. The neurological disorder could consist in consciousness
impairment, a seizure with or without status epilepticus, a focal sign, encephalopathy, and/or
meningeal symptoms. Coma was defined as a score of8.
Data collection
A standardized electronic form was used to collect the study data reported in Tables 1–3 and
Fig 1. Severity and organ dysfunction at ICU admission were assessed using the Simplified
Acute Physiology Score II (SAPS-II)[15] and Sepsis-Related Organ Failure Assessment
(SOFA) score.[16] The SOFA score was also collected routinely on days 2, 3, 5, and 7 after
ICU admission.
Malignancies diagnosed within the past 4 weeks were defined as newly diagnosed. The per-
formance status[5] and Charlson comorbidity index[17] were determined at ICU admission.
Neutropenia was defined as a neutrophil count less than 500/mm3.[18]
Patient management and ICU-admission criteria remained unchanged throughout the
study period. A thorough neurological evaluation including determination of the GCS score
[19, 20] was performed at ICU admission then on days 2, 3, 5, and 7.
Management
Mechanical ventilation was used according to standardized criteria in patients whose GCS
score remained below 8 despite etiological treatment when a reversible cause was suspected
(e.g., status epilepticus or opioid or benzodiazepine poisoning). On-scene intubation was
Table 1. Spectrum of acute organ failures on the first ICU day according to type of hematological malignancy in 1011 patients requiring ICU
admission.
N (%) or Median (Interquartile Range)
All
patients
Non-
Hodgkin’s
lymphoma
Acute
Myeloid
Leukemia
Myeloma Acute
Lymphophocytic
Leukemia
Chronic
Lymphocytic
Leukemia
Myelodysplastic
Syndrome
Hodgkin’s
Disease
Chronic
Myeloid
Leukemia
Other
n = 1011 n = 320 n = 275 n = 126 n = 76 n = 76 n = 46 n = 25 n = 19 n = 51
Organ failures on ICU day 1
Neurological 226
(22.3%)
85 (26.6%) 48 (17.5%) 22
(17.5%)
17 (22.4%) 17 (22.4%) 11 (23.9%) 5(20.0%) 5 (26.3%) 16
(31.4%)
Hemodynamic 428
(42.3%)
146 (45.6%) 106 (38.5%) 51
(40.5%)
30 (39.4%) 33 (43.4%) 29 (63.0%) 11 (44.0%) 7 (36.8%) 15
(29.4%)
Respiratory 632
(62.5%)
177 (55.3%) 173 (62.9%) 85
(67.5%)
38 (50.0%) 56 (73.7) 32 (69.6%) 17 (68.0%) 16 (84.2%) 38
(74.5%)
Hematological 194
(19.2%)
52 (16.3%) 76 (27.6%) 17
(13.5%)
10 (13.2%) 13 (17.1%) 11 (23.9%) 5 (20.0%) 4 (21.1%) 6
(11.7%)
Hepatic 83
(8.2%)
29 (9.1%) 26 (9.4%) 8 (6.3%) 2 (2.6%) 1 (1.3%) 4 (8.7%) 3 (12.0%) 3 (15.8%) 7
(13.7%)
Renal 308
(30.5%)
115 (35.9%) 66 (24.0%) 53
(42.1%)
18 (23.7%) 19 (25%) 12 (26.1%) 5 (20.0%) 5 (26.3%) 15
(29.4%)
Total 2 (1–2) 2 (1–3) 2 (1–2) 2 (1–2) 1 (1–2) 2 (1–3) 2 (1–3) 1(1–2) 2 (1–3) 2(1–2)
https://doi.org/10.1371/journal.pone.0178824.t001
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required in some of the comatose patients. Finally, intubation was also required in some of the
patients with aspiration pneumonia, respiratory failure, shock, or cardiac arrest.
Vasoactive drugs were restricted to patients with hypotension despite fluid resuscitation or
with heart failure documented by echocardiography and evidence of another organ failure
(i.e., oliguria, renal failure, or lactic acidosis). Renal replacement therapy was used according
to previously published criteria.[21] Standard medical treatment for the suspected cause was
introduced immediately after the initial clinical evaluation (e.g., antimicrobials, anticonvul-
sants, or antidotes).
Etiological diagnosis
Computed tomography (CT) or magnetic resonance imaging (MRI) was obtained routinely,
and any abnormal findings were described as focal and/or diffuse and as transient or perma-
nent. Lumbar puncture and intermittent EEG monitoring were performed as needed.
Table 2. Neurological features in 226 patients with hematological malignancies and neurological fail-
ure requiring ICU admission.
All patients
n = 226 (100%)
General signs
Seizures 34 (19.2%)
Nausea and vomiting 26 (14.9%)
Mental status
Headache 20 (11.3%)
Drowsiness or stupor 114 (64.8%)
Coma 72 (32.6%)
Cranial nerves
Any cranial nerve abnormalities 9 (5.1%)
Visual disturbancesa 9 (5.3%)
Motor system
Weakness 44 (25.9%)
Focal neurological signsb 18 (7.9%)
Sphincter tone abnormalities 3 (1.7%)
Sensory system
Any sensory abnormality 4 (2.3%)
Back pain 5 (2.9%)
Radicular pain 2 (1.2%)
Tuft sign 1 (0.6%)
Cerebellar syndrome 2 (1.2%)
Abnormal gait 34 (19.8%)
Meningeal signs 14 (8.0%)
Brainstem signs 1 (0.6%)
Peripheral neurological signs 2 (1.1%)
aDiplopia (n = 3), decreased visual acuity (n = 2), blindness (n = 1), exophthalmia (n = 1), anisocoria (n = 1),
mydriasis (n = 1)
bFocal neurological signs were defined as symptoms or signs consistent with damage to, or dysfunction of, a
specific anatomic site in the central nervous system. Signs were classified as unifocal or multifocal and as
transient or persistent; they consisted of hemiparesis (n = 6), hemiplegia (n = 9), monoparesis (n = 2), and
paraplegia (n = 1).
https://doi.org/10.1371/journal.pone.0178824.t002
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Table 3. Patient characteristics and predictors of hospital mortality identified by logistic regression.
N (%) or Median (InterQuartile Range) Univariate analysis Multivariable analysis
All patients Survivors Nonsurvivors OR (95%CI) P Value OR (95%CI) P value
n = 226 (100%) n = 114 (50.4%) n = 112 (49.6%)
Patient characteristics
Age (years), median (IQR) 63 (53–72) 61 (51–72) 64 (54–72) 1.01 (0.99–1.03) 0.21
Male gender 132 (58.4%) 67 (58.8%) 65 (58.0%) 0.97 (0.57–1.65) 0.91
Poor performance statusa 54 (23.9%) 16 (14.0%) 38 (33.9%) 3.15 (1.63–6.07) 0.0006 4.44 (2.10–9.93) 0.0001
Charlson comorbidity index,
median (IQR)
3 (2–4) 3 (2–4) 2 (2–4) 0.78 (0.49–1.23) 0.28
Characteristics of the underlying malignancy
Classification
Non-Hodgkin’s lymphoma 85 (37.6%) 34 (29.8%) 51 (45.5%) 1.97 (1.14–3.40) 0.01 2.60 (1.35–5.15) 0.005
Acute myeloid leukemia 48 (21.2%) 24 (21.1) 24 (21.4%) 1.02 (0.54–1.93) 0.94
Myeloma 22 (9.7%) 14 (12.3%) 8 (7.1%) 0.55 (0.22–1.37) 0.20
Acute lymphocytic leukemia 17 (7.5%) 12 (10.5%) 5 (4.5%) 0.40 (0.14–1.17) 0.09
Chronic lymphocytic leukemia 17 (7.5%) 12 (10.5%) 5 (4.5%) 0.40 (0.14–1.17) 0.09
Myelodysplastic syndrome 11 (4.9%) 7 (6.1%) 4 (3.6%) 0.57 (0.16–1.99) 0.38
Chronic myeloid leukemia 5 (2.2%) 2 (1.7%) 3 (2.7%) 1.54 (0.25–9.40) 0.64
Hodgkin’s disease 5 (2.2%) 3 (2.6%) 2 (1.8%) 0.67 (0.11–4.10) 0.67
Other 16 (7.1%) 6 (5.3%) 10 (8.9%) 1.76 (0.62–5.03) 0.29
Newly diagnosed 92 (40.7%) 41 (37.3%) 51 (46.8%) 1.48 (0.86–2.54) 0.15
Time since hematologic
malignancy diagnosis (days),
median (IQR)
120 (8–847) 180 (14–1018) 88 (5–482) 1.00 (1.00–1.00) 0.31
Number of previous chemotherapy
lines, median (IQR)
1 (0–2) 1 (0–2) 1 (0–2) 0.96 (0.79–1.16) 0.66
Allogeneic stem cell
transplantation
18 (8.0%) 8 (7.0%) 10 (9.0%) 1.31 (0.50–3.46) 0.58
Autologous stem cell
transplantation
21 (9.3%) 15 (13.2%) 6 (5.4%) 0.38 (0.15–0.97) 0.04 0.25 (0.07–0.75) 0.02
Remission (complete or partial) 47 (22.1%) 32 (29.6%) 15 (14.3%) 0.40 (0.20–0.79) 0.008
Circumstances of ICU
admission
Shock 102 (45.1%) 42 (36.8%) 60 (53.6%) 1.98 (1.16–3.37) 0.01 1.95 (1.04–3.72) 0.04
Acute respiratory failure 130 (57.5%) 56 (49.1%) 74 (66.1%) 2.02 (1.18–3.45) 0.01 2.18 (1.14–4.25) 0.02
Acute kidney injury 69 (30.5%) 28 (24.6%) 41 (36.6%) 1.77 (1.00–3.15) 0.05
GCS score, median (IQR) 12 (7–15) 13 (10–15) 11 (5–14) 0.91 (0.85–0.97) 0.002 0.87 (0.81–0.94) 0.0005
Neutropenia 52 (23.4%) 24 (21.2%) 28 (26.7%) 1.28 (0.69–2.39) 0.43
Severity scores at ICU
admission
SAPS IIb, median (IQR) 58 (47–70) 54 (43–60) 64 (53–80) 1.05 (1.02–1.08) 0.0003
SOFA scoreb, median (IQR) 9 (5–13) 7 (4–10) 11 (8–14) 1.20 (1.11–1.30) < 0.0001
Time to admission since onset of
neurological manifestations (days),
median (IQR)
0 (0–1) 0 (0–1) 0 (0–1) 1.00 (0.99–1.01) 0.41
Cause of neurological
manifestations (one or more)
Direct CNS involvement 11 (4.9%) 6 (5.3%) 5 (4.5%) 0.84 (0.25–2.84) 0.78
CNS infiltration 11 (4.9%) 6 (5.3%) 5 (4.5%) 0.84 (0.25–2.84) 0.78
Indirect CNS involvement 114 (50.4%) 62 (54.4%) 52 (46.4%) 0.73 (0.43–1.23) 0.23
Metabolic 73 (32.3%) 39 (34.2%) 34 (30.4%) 0.84 (0.48–1.47) 0.54
(Continued )
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Cerebrospinal fluid (CSF) abnormalities were defined as a cell count>5/μL, protein >45 mg/
dL, glucose <0.5 blood glucose, organisms, and/or atypical cells.[22] Electrical seizure activity
was defined as continuous or recurrent, rhythmic, focal or generalized spikes; sharp waves;
spike waves; or rhythmic waves changing in amplitude, frequency, and/or spatial distribution.
[23] Laboratory tests were obtained routinely to look for metabolic abnormalities associated
with neurological manifestations such as disturbances in serum sodium, calcium, urea, or glu-
cose. Blood cell counts and coagulation tests were done to assess the bleeding risk. Plasma anti-
convulsant-drug assays and qualitative tests for toxic substances or medications associated
with coma were performed as indicated by the clinical history. A neurosurgical biopsy was per-
formed only when focal lesions visualized by cerebral imaging studies remained of unknown
or doubtful nature despite extensive investigations. The bedside physician was asked whether
the etiological investigations contributed directly to the final diagnosis.
In each patient, the etiologic diagnosis was made by consensus among the intensivists,
hematologists, and consultant neurologists. CNS infiltration by the malignant cells was diag-
nosed in patients meeting at least two of the following criteria: positive autopsy or biopsy, typi-
cal neuroimaging findings, atypical cells identified by cytology and/or histopathology in
marrow smears or bone biopsies, and/or neuroimaging and clinical response to specific che-
motherapy. Drug-related neurological complications were defined as adverse neurological
events occurring after exposure to a drug known to induce neurological toxicity. Cerebrovas-
cular disease was diagnosed based on neuroimaging evidence of acute ischemic or hemor-
rhagic stroke, cerebral venous thrombosis, or subarachnoid hemorrhage.
Table 3. (Continued)
N (%) or Median (InterQuartile Range) Univariate analysis Multivariable analysis
All patients Survivors Nonsurvivors OR (95%CI) P Value OR (95%CI) P value
n = 226 (100%) n = 114 (50.4%) n = 112 (49.6%)
Iatrogenic 15 (6.6%) 11 (9.6%) 4 (3.6%) 0.35 (0.11–1.12) 0.08
Vascular damage 14 (6.2%) 7 (6.1%) 7 (6.3%) 1.02 (0.35–3.01) 0.97
CNS infection 12 (5.3%) 5 (4.4%) 7 (6.3%) 1.45 (0.45–4.72) 0.53
Nonneurological cause 77 (34.1%) 35 (30.7%) 42 (37.5%) 1.35 (0.78–2.35) 0.28
Shock 52 (23.0%) 23 (20.2%) 29 (25.9%) 1.38 (0.74–2.58) 0.31
Cardiac arrest 15 (6.6%) 4 (3.5%) 11 (9.8%) 3.00 (0.92–9.71) 0.07
Sepsis 10 (4.4%) 8 (7.0%) 2 (1.8%) 0.24 (0.05–1.16) 0.07
Undetermined 24 (10.6%) 11 (9.6%) 13 (11.6%) 1.23 (0.53–2.87) 0.63
Treatment in the ICU
Catecholamine support 132 (58.4%) 45 (39.5%) 87 (77.7%) 5.34 (2.98–9.55) <0.0001
Noninvasive ventilation 46 (20.4%) 20 (17.5%) 26 (23.2%) 1.42 (0.74–2.73) 0.29
Mechanical ventilation 154 (68.1%) 59 (51.7%) 95 (84.8%) 5.21 (2.76–9.82) <0.0001
Dialysis 62 (27.4%) 21 (18.4%) 41 (36.6%) 2.56 (1.39–4.71) 0.003
Emergent anticancer
chemotherapy
11 (4.9%) 7 (6.1%) 4 (3.6%) 0.57 (0.16–1.99) 0.38
Data are number (%) unless otherwise specified. ICU, intensive care unit; SAPS II, Simplified Acute Physiology Score; SOFA score, Sequential Organ
Failure Assessment score; OR, odds ratio; 95%CI, 95% confidence interval. Goodness of fit (Le Cessie-Van Houweligen) chi-square P = 0.94; the area
under the ROC curve estimated by the c statistic was 0.77; P values indicating a significant difference (<0.05) are in bold type.
abedridden/completely disabled
bHigher scores indicate greater severity.
https://doi.org/10.1371/journal.pone.0178824.t003
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Metabolic CNS injury was considered when neuroimaging and CSF studies were normal
and laboratory tests showed metabolic disturbances. Finally, CNS infection was diagnosed in
patients with clinical evidence of sepsis, positive serological and/or microbiological tests on
CSF.
Statistical analysis
Quantitative parameters are reported as median and interquartile range (IQR, 25th -75th
percentile) and qualitative parameters as number and percentage. Categorical variables were
compared using the χ2 test or Fisher’s exact test, as appropriate. Continuous variables were
compared using the Mann-Whitney U test or Wilcoxon test, as appropriate.
The primary outcome was vital status at hospital discharge, which was known for all
patients. Associations linking patient characteristics to hospital mortality were assessed using a
logistic regression model. Factors included in the multivariate regression model were selected
among variables yielding P values smaller than 0.05 and/or were clinically relevant by univari-
ate analysis. A stepwise procedure based on the Akaike Information Criterion was used to
build the final multivariate model. Log-linearity of continuous variables was checked. Good-
ness of fit was evaluated by applying the Le Cessie-Van Houweligen test to the final models.
Odds ratios (OR) and their 95% confidence intervals (95%CI) were computed. The secondary
objective was to identify associations between patient characteristics and 1-year mortality. A
Cox proportional hazard model was built for each variable and the proportional hazards
assumption was assessed using Schoenfeld residuals. A multivariate model was built with vari-
ables that yielded P values smaller than 0.05 by univariate analysis and/or were clinically rele-
vant (Survival R-package). There were 67 observations deleted due to missingness. One-year
adjusted survival curves for cox proportional hazards model are reported according to neuro-
logical failure occurrence (Survminer R-package). P values less than 0.05 were considered sta-
tistically significant. Analyses were done using R software version 3.1.2. (online at http://www.
R-project.org).
Results
Study population
Fig 1 is the study flow chart. In the 1011 patients with hematological malignancies who
required ICU admission, the median number of organ failures was 2 (IQR 1–2) and varied
across underlying diseases (Table 1). Neurological failure was the fourth most common organ
failure, with 226 (22.4%) patients at ICU admission. The main characteristics of these 226
patients are reported in Fig 1.
A history of cancer chemotherapy within 30 days before ICU admission was noted in 95
(42%) patients, and 15 (6.6%) patients had received radiotherapy.
Neurological presentation at ICU admission
Table 2 lists and Fig 2 illustrates the neurological features at ICU admission. Median GCS
score was 12 (7–15). Neuroimaging, lumbar puncture, and electroencephalography were per-
formed in 113 (50%), 73 (32%), and 63 (28%) patients, respectively, and were deemed directly
contributive to the final diagnosis in 51 (45%), 18 (25%), and 43 (38%) patients, respectively. A
neurosurgical biopsy was performed in a single patient and provided the etiological diagnosis.
Neurological involvement was direct in 11 (5%) patients, due to indirect neurological factors
in 114 (50%) patients (metabolic, n = 73; CNS infection, n = 12; vascular damage, n = 14, and
iatrogenic, n = 15), due to indirect nonneurological factors in 77 (34%) patients (shock, n = 52;
Neurological failure in ICU patients with hematological malignancies
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Fig 1. Patient flow chart. a defined as bedridden or completely disabled. b number of organ failures at ICU admission defined
according to the SOFA score. c investigations for a cause. First value indicates total number, and second value indicates when
the exploration was deemed directly contributive to the final diagnosis.
https://doi.org/10.1371/journal.pone.0178824.g001
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sepsis, n = 10; and cardiac arrest, n = 15), and due to unidentified factors in 24 (11%) patients.
The anatomic sites of involvement were as follows: hemispheres, n = 200 (88%); meninges,
n = 5 (2%); brainstem, n = 2; cerebellum and/or spinal cord, n = 1; and undetermined, n = 17
(8%).
ICU management
The median SAPS II at ICU admission was 58 (47–70) and the median SOFA score on the day
after ICU admission was 9 (5–13) indicating a total of 3 (2–3) organ failures. At ICU admis-
sion, endotracheal mechanical ventilation was required in 124 (54.9%) patients and noninva-
sive ventilation in 17 (7.5%) patients. Table 3 provides further data on ICU management.
Outcomes after ICU admission
In the 226 patients with neurological failure, ICU and hospital stay lengths were 5 (2–12) and
30 (11–48) days, respectively. Hospital mortality was 49.6%. Mortality was 53.6% on day 30
Fig 2. Neurological signs and symptoms in 226 patients with hematological malignancies and neurological failure requiring ICU admission.
https://doi.org/10.1371/journal.pone.0178824.g002
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after ICU admission and 58.4% after 1 year. Survival after 1 year was not significantly lower in
the 226 patients with neurological failure than in the other 785 patients (aHR, 1.12; 95%CI,
0.91–1.38; P = 0.28) (S1 Table and Fig 3).
Determinants of hospital mortality
By multivariate analysis, independent predictors of higher hospital mortality were poor perfor-
mance status (OR, 3.99; 95%CI, 1.82–9.39; P = 0.0009), non-Hodgkin’s lymphoma (OR, 2.60;
95%CI, 1.35–5.15; P = 0.005), shock (OR, 1.95; 95%CI, 1.04–3.72; P = 0.04), and respiratory
failure (OR, 2.18; 95%CI, 1.14–4.25; P = 0.02). Factors associated with lower hospital mortality
were a higher GCS score on day 1 (OR, 0.88/point; 95%CI, 0.81–0.95; P = 0.0009) and autolo-
gous stem cell transplantation (OR, 0.25; 95%CI, 0.07–0.75; P = 0.02).
Discussion
This multicenter cohort study is the largest to date providing prospective data on neurological
complications in critically ill patients with hematological malignancies. Neurological failure
Fig 3. One-year adjusted survival curves for cox proportional hazards model with (blue line) and without (red line) neurological failure at ICU
admission.
https://doi.org/10.1371/journal.pone.0178824.g003
Neurological failure in ICU patients with hematological malignancies
PLOS ONE | https://doi.org/10.1371/journal.pone.0178824 June 9, 2017 10 / 15
was common, protean in its presentation, and related chiefly to indirect factors, both neuro-
logical and nonneurological. Mortality was high, with most deaths occurring within the first
month. By multivariate logistic regression analysis, autologous stem cell transplantation was
associated with higher short-term survival; factors associated with lower survival were type of
hematological malignancy, poor performance status, hemodynamic and respiratory failures,
and degree of consciousness impairment.
Studies have described the management and outcome of critically ill patients with hemato-
logical malignancies and multiple organ failures, which included neurological failure in 2.4%
to 16.9% of cases. The study designs vary but are usually retrospective, the study periods differ,
and neurological failure was often defined as coma, so that no data on the many other presen-
tations are reported.[24–29] Of the few studies evaluating the neurological complications of
malignancies, one was retrospective and confined to critically ill patients with any type of
malignancy admitted over the 8-year period from 2000 to 2007[10] and another included only
patients who had malignancies treated with hematopoietic transplantation.[30] Here, we
sought to avoid previous methodological shortcomings by using a prospective multicenter
design and a previously validated definition of neurological failure that better reflects the pre-
sentations seen in everyday practice.
Neurological failure occurred in 22.4% of all ICU patients with hematological malignancies.
Non-Hodgkin’s lymphoma and acute myeloid leukemia were the most common diseases.
Compared to our earlier study,[10] the proportion of newly diagnosed hematological malig-
nancies was considerably higher (40% vs. 16%), whereas findings were similar for the time
from malignancy diagnosis to neurological failure and for the proportions of patients in remis-
sion, having received chemotherapy within the last 4 weeks, having a history of hematopoietic
transplantation, or having neutropenia at presentation.[10]
The full spectrum of neurological complications of hematological malignancies was repre-
sented. The high proportion of patients with seizures (19.2%) may be ascribable to the nature
of the malignancies in our population. In earlier studies, seizures occurred in 5% of patients
after hematopoietic transplantation,[30] 8% of patients with non-Hodgkin’s lymphoma,[31]
and 20% of patients with acute myeloid leukemia.[32] Another factor may be that some of our
patients had postanoxic status epilepticus after cardiac arrest.[10, 33] The cause of neurological
failure was identified in the vast majority of our patients. Depending on the nature of the
investigation, a direct contribution to the diagnosis was reported in 25% to 100% of cases. The
previously used classification into direct and indirect causes of CNS involvement proved inad-
equate in describing the full spectrum of cases.[11, 13] Thus, nonneurological causes such as
cardiac arrest,[2] severe sepsis, and shock were involved in about one-third of cases. The pro-
portions of patients with other causes were in keeping with our earlier report.[10]
Most patients had multiple organ failures at ICU admission. Mechanical ventilation was the
most often used life-supporting intervention, probably because many patients were comatose.
Catecholamines and dialysis were also often required at ICU admission. This high level of life
support is consistent with the changes in management strategies that have accompanied recent
advances in the management of malignancies.[3, 4, 34, 35] ICU admission criteria have been
developed jointly by hematologists and intensivists, in particular to ensure early admission of
patients with incipient organ failure, and full-code treatment is then given routinely until
reevaluation of the prognosis after a few days.[8, 9]
Despite the extensive etiological investigations and high level of organ support, mortality
was high, with nearly half the patients dying in the hospital. Among 57 non-ICU patients with
neurological complications after hematopoietic transplantation, 21 (37%) died.[30] In a single-
center retrospective study of 124 critically ill patients with hematological malignancies, mortal-
ity in the subgroup admitted for neurological impairment was 33%.[24] Another retrospective
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study, in 100 patients admitted to the ICU for neurological failure, found an inhospital mortal-
ity rate of 45%.[10] After hematopoietic transplantation, the occurrence of neurological com-
plications was associated with mortality.[30]
We identified several factors independently associated with hospital mortality. Autologous
stem cell transplant recipients are generally at high risk for death, and their better survival in
our study reflects good selection of patients likely to benefit from ICU admission. However,
despite the use of effective ICU-admission criteria, poor performance status, hemodynamic
and respiratory failure in addition to neurological failure, and greater coma severity were asso-
ciated with a higher risk of death. Finally, hospital mortality was higher in patients with non-
Hodgkin’s lymphoma, in keeping with the nearly exclusive occurrence of CNS involvement in
the aggressive forms of this disease, which are also associated with high mortality.[36],[37, 38]
Our study has several limitations. Consultants were available around the clock in the
participating centers, and our findings may not apply to hospitals where this is not the case.
Although great care was taken to identify, report, and explain neurological involvement in our
prospective cohort of 1011 ICU patients with hematological malignancies, this study is a post-
hoc analysis. However, the standardized form used to prospectively collect data on neurologi-
cal involvement, combined with the participation of 17 university or university-affiliated cen-
ters, provides a comprehensive picture of the management and prognosis of the population of
interest. The etiology was identified and treated in the vast majority of patients. Finally, the
ICU-admission criteria may have varied across study centers. However, the proportions of
patients who were refused ICU admission did not differ significantly across centers, and
refusal was not associated with hospital mortality.
In conclusion, in patients with hematological malignancies who require ICU admission,
neurological failure is common and associated with a high risk of death. Factors independently
associated with death are type of malignancy, poor performance status, hemodynamic and
respiratory failures, and severe consciousness impairment. Knowledge of these risk factors
may help to improve management strategies.
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